78 related articles for article (PubMed ID: 10725546)
21. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Clayton R; Ohagen A; Nicol F; Del Vecchio AM; Jonckers TH; Goethals O; Van Loock M; Michiels L; Grigsby J; Xu Z; Zhang YP; Gutshall LL; Cunningham M; Jiang H; Bola S; Sarisky RT; Hertogs K
Antiviral Res; 2009 Nov; 84(2):142-9. PubMed ID: 19699239
[TBL] [Abstract][Full Text] [Related]
22. Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Hashimoto KI; Tsunoda R; Okamoto M; Shigeta S; Baba M
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):193-9. PubMed ID: 9007205
[TBL] [Abstract][Full Text] [Related]
23. Exposure of resting peripheral blood T cells to HIV-1 particles generates CD25+ killer cells in a small subset, leading to induction of apoptosis in bystander cells.
Kameoka M; Suzuki S; Kimura T; Fujinaga K; Auwanit W; Luftig RB; Ikuta K
Int Immunol; 1997 Oct; 9(10):1453-62. PubMed ID: 9352350
[TBL] [Abstract][Full Text] [Related]
24. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
25. Production of infectious particles from defective human immunodeficiency virus type 1 (HIV-1)-producing cell clones by superinfection with infectious HIV-1.
Yunoki M; Maotani-Imai K; Kusuda H; Motoyama M; Miyake S; Imai H; Shin YS; Kato S; Sano K; Morita C
Arch Virol; 1991; 116(1-4):143-58. PubMed ID: 2001175
[TBL] [Abstract][Full Text] [Related]
26. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.
Paolucci S; Baldanti F; Dossena L; Gerna G
Antiviral Res; 2006 Mar; 69(3):181-5. PubMed ID: 16460817
[TBL] [Abstract][Full Text] [Related]
27. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
[TBL] [Abstract][Full Text] [Related]
28. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.
Karlsson AC; Deeks SG; Barbour JD; Heiken BD; Younger SR; Hoh R; Lane M; Sällberg M; Ortiz GM; Demarest JF; Liegler T; Grant RM; Martin JN; Nixon DF
J Virol; 2003 Jun; 77(12):6743-52. PubMed ID: 12767994
[TBL] [Abstract][Full Text] [Related]
29. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.
Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S
AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082
[TBL] [Abstract][Full Text] [Related]
30. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
[TBL] [Abstract][Full Text] [Related]
31. HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient Contacts.
Symeonides M; Murooka TT; Bellfy LN; Roy NH; Mempel TR; Thali M
Viruses; 2015 Dec; 7(12):6590-603. PubMed ID: 26703714
[TBL] [Abstract][Full Text] [Related]
32. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
Appadurai R; Senapati S
Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
[TBL] [Abstract][Full Text] [Related]
33. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
35. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
Stratov I; Dale CJ; Chea S; McCluskey J; Kent SJ
J Virol; 2005 Jun; 79(12):7728-37. PubMed ID: 15919925
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of fusion receptors for human T-cell leukemia virus type-I (HTLV-I) and human immunodeficiency virus type-1 (HIV-1) on MOLT-4 cells.
Kannagi M; Kuroda MJ; Maeda Y; Harada S
Microbiol Immunol; 1991; 35(9):729-40. PubMed ID: 1687290
[TBL] [Abstract][Full Text] [Related]
37. Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.
Ott DE; Coren LV; Chertova EN; Gagliardi TD; Nagashima K; Sowder RC; Poon DT; Gorelick RJ
J Virol; 2003 May; 77(10):5547-56. PubMed ID: 12719547
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
40. The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles.
Chen SW; Chiu HC; Liao WH; Wang FD; Chen SS; Wang CT
Virology; 2004 Jan; 318(2):534-41. PubMed ID: 14972522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
